IMFINZI 50 mg/mL concentrate for solution for infusion. clinical trials
31 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract. iNDUCT - GETUG V08
This study is looking at a new combination of treatments for a type of bladder or kidney cancer which has not spread. It combines a new drug (Durvalumab) with standard chemotherapy to see if it can shrink the cancer before surgery, aiming to remove all cancer cells.
For: The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter.France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II trial of radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck (REWRITe)
This study is looking at a new way to treat head and neck cancer. It combines standard radiotherapy with a new drug called durvalumab, and aims to see if we can reduce the need for surgery in the neck, while still controlling the cancer.
For: Untreated squamous cell carcinoma of the head and neckFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Tremelimumab (Day 1 only), Durvalumab (MEDI4736) and Trans-arterial catheter chemoembolization (TACE)in patients with advanced Hepatocellular Carcinoma (HCC)
This study is looking at a new combination of medicines and a treatment called TACE for people with advanced liver cancer. It aims to see if this combination can stop the cancer from growing for at least 6 months and if it's safe.
For: Advanced Hepatocellular Carcinoma (HCC)Ireland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection
This study is checking a new medicine called Imdusiran alongside an existing one, Durvalumab (Imfinzi), for people with long-term Hepatitis B. Researchers want to see if this combination is safe, how well people tolerate it, and how it affects the body.
For: Chronic HBV InfectionFrance · Spain · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03)
This study looks at new treatments for a type of lung cancer that has not spread widely. It compares two drug combinations to see which is better at stopping the cancer from growing after initial treatment.
For: Non−small cell lung cancer (NSCLC)Poland · Spain · Portugal - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
ABIMMUNE: A Phase I/II study evaluating the safety and clinical activity of anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) antibodies administrated in combination with stereotactic body radiotherapy (SBRT) in patients with metastatic squamous cell carcinoma of head and neck, lung, oesophageus, cervix, vagina, vulva or anus.
This study looks at combining new cancer drugs with a special type of radiation for specific cancers that have spread. We want to see if this treatment is safe and if it helps shrink tumours. It's for certain cancers in the head, neck, lung, food pipe, and female private parts.
For: Metastatic squamous cell carcinoma of head and neck · lung · esophagusFrance - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
This study looks at new drug combinations for advanced breast cancer that has spread. It focuses on a type of breast cancer called 'HER2-low'. Doctors want to see if these combinations are safe, how they work in the body, and if they can help shrink tumours.
For: Metastatic Breast CancerBelgium - AuthorisedTherapeutic exploratory (Phase II)
An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
This study looks at a new treatment called Durvalumab (IMFINZI) combined with chemotherapy before surgery for bladder cancer. Researchers want to see if this combination causes any serious side effects and how well it works in patients with muscle-invasive bladder cancer.
For: Patients With Muscle-Invasive Bladder CancerItaly · Spain · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Cancer
This study looks at new treatments for advanced bladder cancer that can’t be removed by surgery. It compares two new medicines, alone or together, against standard chemotherapy to see which helps people live longer and stops cancer from growing.
For: ureters · urinary bladder · and urethra)Spain · Greece - Ongoing, recruitingTherapeutic exploratory (Phase II)
IFCT-1802 SAVIMMUNE A phase II single-arm trial evaluating safety and efficacy of Durvalumab in ECOG Performance Status 2-3, treatment-naive, patients with stage IV Non-Small Cell Lung Cancer (NSCLC) and high PD-L1 tumor expression
This study looks at a new cancer treatment called durvalumab (Imfinzi) for people with a type of advanced lung cancer. It aims to see how safe the treatment is and if it helps people feel better. It focuses on patients who are quite unwell at the start.
For: Non small cell lung cancer · Poor general statusFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Nonsmall Cell Lung Cancer (LA NSCLC)
This study is looking at new ways to treat a type of lung cancer that hasn't spread widely. It compares standard treatments with new drug combinations to see if they can stop the cancer from growing for longer. It aims to find the best treatment for patients with this type of lung cancer.
For: Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)France · Netherlands · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carcinoma. A non-comparative randomized phase II study
This study looks at treating bile duct cancer after surgery. Patients will receive either standard chemotherapy (capecitabine) or a combination of chemotherapy and a newer immune-boosting drug (durvalumab, also known as Imfinzi). The main goal is to see if the new combination helps people stay cancer-free for longer.
For: Biliary tract carcinomaFrance - Ongoing, recruitingPhase III and phase IV (Integrated)
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC (KEYVIBE-006)
This study is looking at new ways to treat advanced lung cancer that can't be removed by surgery. It compares a new combination of medicines with a standard treatment, both given with chemotherapy and radiotherapy, to see which works best.
For: Non-small cell lung cancerSpain · Italy · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
ETOP 21-21 BOUNCE: A multicentre, randomised, phase II trial of brigatinib consolidation versus observation or durvalumab in patients with unresectable stage III NSCLC and ALK-rearrangement, after definitive chemo-radiotherapy.
This study is for people with a type of lung cancer called NSCLC with a specific gene change (ALK-rearrangement). It's looking at whether a drug called Brigatinib, given after chemotherapy and radiation, can stop the cancer from growing for longer compared to other treatments or no further treatment.
For: Non-small cell lung cancer (NSCLC)Spain · Italy · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1)
This study is testing new ways to treat a type of liver cancer that hasn't spread far. It combines a standard treatment (TACE) with new medicines (durvalumab, sometimes with bevacizumab) to see if they help people live longer without their cancer growing.
For: Locoregional Hepatocellular Carcinoma (HCC)Italy · France · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)
This study is looking at a new medicine called IMFINZI for people in the UK with advanced lung cancer who have already had at least two different treatments. It wants to see how well the medicine shrinks tumours and helps people live longer, while also checking for any side effects.
For: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIBIV)Belgium - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab (Medi4736) for patients with recurrent glioblastoma
This study looks at combining a new type of radiation therapy with a drug called Durvalumab (Imfinzi) for people with a brain tumour called glioblastoma that has come back. It aims to see if this treatment is safe and if it helps people live longer.
For: Recurrent glioblastoma.France - Ongoing, recruitingTherapeutic exploratory (Phase II)
Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy - Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy
This study looks at a new way to treat lung cancer for older or frailer patients. It combines a special type of radiation therapy with a drug called durvalumab (Imfinzi). The aim is to see if this treatment is safe and effective in shrinking tumors in people who can't have standard chemotherapy.
For: unresectable stage III NSCLC (Non–small-cell lung cancer)Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJUvant situation for BILiary tract cancer
This study is looking at new treatments for a type of cancer called biliary tract cancer after surgery. It combines existing cancer drugs with new immunotherapy drugs, durvalumab and tremelimumab. The aim is to see if these combinations can stop the cancer from coming back and improve how long people live well.
For: Biliary tract cancerGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients with BRCA Mutations and Early Stage HER2- negative Breast Cancer (OlympiaN)
This study is looking at new ways to treat a specific type of early breast cancer in people with a gene change called a BRCA mutation. It tests two medicines, olaparib alone and olaparib with durvalumab, to see how well they shrink tumours before surgery and if they are safe.
For: BRCA Mutations and Early Stage HER2-Negative Breast CancerGermany · Belgium · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study
This study looks at new ways to treat advanced soft tissue sarcoma, a type of cancer. It uses special tests to check for changes in cancer cells and aims to find the best medicine for each person, making sure these tests are practical and quick enough.
For: Unresectable locally advanced and/or metastatic soft-tissue sarcomaFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
This study looks at new treatments for advanced ovarian cancer. It combines standard chemotherapy with newer drugs, durvalumab and bevacizumab, and then adds olaparib. We want to see if this combination helps patients live longer without their cancer growing.
For: Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian · fallopian or primary peritoneal cancerBelgium · Italy · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum-Based Chemotherapy with Durvalumab in First Line Stage IV NonSmall Cell Lung Cancer (ORION)
This study looks at a new combination treatment for advanced lung cancer that hasn't spread further after initial chemotherapy. It compares two medicines, Durvalumab and Olaparib, given together, to Durvalumab alone. We want to see if the combination helps patients live longer without their cancer growing.
For: Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusionsPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)
This study is testing a new combination of medicines before surgery for a rare type of liver cancer called intrahepatic cholangiocarcinoma. It aims to see if these medicines can help more patients have successful surgery by making the tumour smaller or easier to remove.
For: intrahepatic cholangiocarcinomaGermany - Ongoing, recruitingPhase I and Phase II (Integrated)- Bioequivalence Study
MOVIE_A phase I/II basket trial evaluating a combination of Metronomic Oral Vinorelbine plus anti-PD-L1/anti-CTLA4 ImmunothErapy in patients with advanced solid tumours.
This study looks at a new combination treatment for advanced cancers. It combines a low, regular dose of vinorelbine (a chemotherapy drug) with two immunotherapy drugs (durvalumab and tremelimumab), aiming to find the safest dose and see how well it works.
For: Patients with locally advanced or metastatic solid tumoursFrance - AuthorisedTherapeutic exploratory (Phase II)
Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC
This study is looking at a new way to treat an advanced type of lung cancer called extensive stage small cell lung cancer. It combines standard treatments like chemotherapy and radiotherapy with a new drug called Durvalumab (Imfinzi) to see if it can stop the cancer from growing for longer.
For: extensive stage small cell lung cancer (SCLC)Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
CAIRE : COMBINING EPIGENETIC AND IMMUNE THERAPY TO BEAT CANCER
This study looks at combining two medicines, Tazemetostat and Imfinzi, to treat certain advanced cancers. Researchers want to see if this combination can stop cancer from growing or shrink it in patients with advanced pancreatic, bowel, or soft tissue cancers, and other specific advanced solid tumours.
For: Adult participants with metastatic or unresectable locally advanced solid tumors.France - AuthorisedTherapeutic exploratory (Phase II)
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer.
This study is looking at new ways to treat advanced ovarian cancer that has come back. It tests combinations of new drugs, olaparib, durvalumab, and a vaccine called UV1, to see if they can stop the cancer from growing for longer in patients whose cancer does not have a specific BRCA gene change.
For: Ovarian cancerNetherlands · Finland · Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III) (PACIFIC2)
This study looks at a new drug called Imfinzi for people with a type of lung cancer that has spread nearby but can't be removed by surgery. It aims to see if Imfinzi, along with standard treatments like chemotherapy and radiation, helps people live longer and keeps the cancer from growing.
For: Patients with Locally Advanced · Unresectable Non-small Cell Lung Cancer (Stage III)Poland · Hungary - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Durvalumab (MEDI4736 ) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity study
This study looks at new drug combinations before surgery for a type of mouth cancer. Researchers want to see if these drugs can boost the body's immune response inside the cancer. It's an early-stage study to understand if these treatments could be helpful and safe for patients.
For: Resectable · locally advanced squamous cell carcinoma of the oral cavity.Belgium - AuthorisedTherapeutic exploratory (Phase II)
Phase II, clinical trial, to evaluate OS in two cohorts in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumab
This study is looking at a new treatment called IMFINZI for advanced lung cancer. It wants to see if IMFINZI can help people live longer, especially those whose cancer has come back after other treatments. The study is also checking if the treatment is safe and how well it works.
For: NSCLC non-small cell lung cancerItaly